10A1P16
10A1P16 is an ionizable phospholipid composed of a tertiary amine, a phosphate group and three hydrophobic tails. As a spleen-selective RNA delivery vector, 10A1P16 successfully transfects approximately 30% of splenic macrophages and 6% of splenic B cells in vivo. 10A1P16 can be used to prepare spleen-selective 10A1P16-MDOA lipid nanoparticles, which effectively mediate mRNA delivery and gene editing in mouse models. This delivery system retains potent spleen-targeted mRNA delivery efficacy and can be applied to ovarian cancer research.
For research use only. We do not sell to patients.
- CAS No.: 2760467-77-2
- Formula: C38H80NO4P
- Molecular Weight:646.02
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
10A1P16 iPLNPs (50 ng mRNA per well; 24 h) mediate high mRNA delivery efficacy in IGROV-1 ovarian cancer cells as part of a single zwitterion, three-tailed iPhos subgroup with a ~60% in vitro hit rate[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
10A1P16-MDOA iPLNs (i.v.; single dose) enable spleen-selective gene editing in Ai9 reporter mice, transfecting ~30% of splenic macrophages and 6% of splenic B cells[1].
The 10A1P16-based iPLNP formulation achieves spleen-selective RNA delivery in wild-type mice, transfecting 30% of splenic macrophages and 6% of splenic B cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 Mice (female, 6-8 weeks old)[1]
-
Dosage:0.1 mg/kg luciferase mRNA; 0.25 mg/kg luciferase mRNA
-
Administration:i.v.; single dose
-
Result:Mediated selective luciferase mRNA expression in the spleen.
Chemical Information
-
CAS No. 2760467-77-2
-
Molecular Weight 646.02
-
Formula C38H80NO4P
-
SMILES
O=P(OCCCCCCCCCCCCCCCC)([O-])OCC[NH+](CCCCCCCCCC)CCCCCCCCCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Gene Editing
Gene editing modify specific sites within the genome through gene deletions, insertions or conversions to study functionally unknown genes or conduct gene therapy. It is also used to change the biological traits of organisms to establish new varieties. Gene editing techniques include zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas 9) (CRISPR/Cas9).
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
CRISPR-Cas9 editing of human pluripotent stem cells
CRISPR-Cas9 editing of human pluripotent stem cells uses a guide RNA to direct Cas9 to a genomic target, where Cas9 creates a double-strand break that is repaired mainly by non-homologous end joining for knockout mutations or by homology-directed repair when a donor template is supplied for precise knock-in or sequence correction. The readout is generated by genotyping edited bulk populations or single-cell-derived clones, using PCR, sequencing, restriction-based assays, reporter fluorescence, or allele-specific analysis to distinguish unedited alleles, indels, precise donor-mediated edits, biallelic deletions, and unwanted on-target lesions.
Purity & Documentation
References
[1]. Liu S, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing[J]. Nature materials, 2021, 20(5): 701-710. [Content Brief]
[2]. Song D, et al. Tuning lipid nanoparticles for RNA delivery to extrahepatic organs[J]. Advanced Materials, 2024, 36(44): 2401445. [Content Brief]
[3]. Fu L, et al. ‘Passive’nanoparticles for organ-selective systemic delivery: design, mechanism and perspective[J]. Chemical Society Reviews, 2023, 52(21): 7579-7601. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)